You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDocetaxel
Accession NumberDB01248  (APRD00932)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionDocetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.
Structure
Thumb
Synonyms
Docetaxel anhydrous
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
TXL
External Identifiers
  • RP-6976
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DocefrezKitSun Pharma Global FZE2011-05-03Not applicableUs
DocetaxelInjection, solution20 mg/mLIntravenousMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2011-06-08Not applicableUs
DocetaxelInjection, solution, concentrate20 mg/2mLIntravenousPfizer Laboratories Div Pfizer Inc2014-06-23Not applicableUs
DocetaxelInjection, solution, concentrate20 mg/mLIntravenousAccord Healthcare Inc.2012-07-01Not applicableUs
DocetaxelInjection, solution80 mg/4mLIntravenousNorthstar Rx LLC2016-01-01Not applicableUs
DocetaxelInjection, solution20 mg/mLIntravenousHospira, Inc.2016-06-28Not applicableUs
DocetaxelInjection, solution, concentrate20 mg/mLIntravenousWinthrop U.S.2010-10-21Not applicableUs
DocetaxelInjection, solution, concentrate20 mg/mLIntravenousActavis Pharma, Inc.2014-09-01Not applicableUs
DocetaxelInjection, solution10 mg/mLIntravenousSandoz Inc2015-07-22Not applicableUs
DocetaxelInjection, solution, concentrate80 mg/8mLIntravenousPfizer Laboratories Div Pfizer Inc2014-06-23Not applicableUs
DocetaxelInjection, solution, concentrate20 mg/mLIntravenousAccord Healthcare Inc.2013-05-15Not applicableUs
DocetaxelInjection, solution, concentrate80 mg/4mLIntravenousWinthrop U.S.2010-10-21Not applicableUs
DocetaxelInjection, solution, concentrate160 mg/8mLIntravenousWinthrop U.S.2016-10-23Not applicableUs
DocetaxelInjection, solution, concentrate20 mg/mLIntravenousActavis Pharma, Inc.2015-10-13Not applicableUs
DocetaxelInjection, solution10 mg/mLIntravenousSandoz Inc2011-06-29Not applicableUs
DocetaxelInjection, solution20 mg/mLIntravenousHospira, Inc.2016-06-28Not applicableUs
DocetaxelInjection, solution, concentrate200 mg/20mLIntravenousPfizer Laboratories Div Pfizer Inc2014-06-23Not applicableUs
DocetaxelInjection, solution, concentrate20 mg/mLIntravenousActavis Pharma, Inc.2014-09-01Not applicableUs
DocetaxelKitAccord Healthcare Inc.2011-06-30Not applicableUs
DocetaxelInjection, solution20 mg/mLIntravenousMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2011-06-08Not applicableUs
DocetaxelInjection, solution20 mg/mLIntravenousHospira, Inc.2016-06-28Not applicableUs
DocetaxelInjection, solution10 mg/mLIntravenousHospira, Inc.2011-03-08Not applicableUs
DocetaxelInjection, solution, concentrate20 mg/mLIntravenousActavis Pharma, Inc.2014-09-01Not applicableUs
DocetaxelKitAccord Healthcare Inc.2011-06-30Not applicableUs
DocetaxelInjection, solution20 mg/mLIntravenousNorthstar Rx LLC2016-01-01Not applicableUs
Docetaxel for InjectionSolution10.0 mgIntravenousHospira Healthcare Corporation2011-03-01Not applicableCanada
Docetaxel InjectionSolution10 mgIntravenousSandoz Canada Incorporated2016-06-02Not applicableCanada
Docetaxel InjectionSolution80 mgIntravenousTeva Canada Limited2014-03-28Not applicableCanada
Docetaxel InjectionSolution20 mgIntravenousAccord Healthcare Inc2015-02-27Not applicableCanada
Docetaxel InjectionSolution20 mgIntravenousBiolyse Pharma CorporationNot applicableNot applicableCanada
Docetaxel InjectionSolution20 mgIntravenousTeva Canada Limited2014-03-28Not applicableCanada
Docetaxel Non-alcohol FormulaInjection20 mg/mLIntravenousEagle Pharmaceuticals, Inc.2016-01-15Not applicableUs
Docetaxel WinthropInjection, solution, concentrate80 mg/4mlIntravenousAventis Pharma S.A.2007-04-20Not applicableEu
Docetaxel WinthropInjection, solution, concentrate160 mg/8mlIntravenousAventis Pharma S.A.2007-04-20Not applicableEu
Docetaxel WinthropInjection, solution, concentrate20 mg/1mlIntravenousAventis Pharma S.A.2007-04-20Not applicableEu
PMS-docetaxelKit; Solution20 mgIntravenousPharmascience IncNot applicableNot applicableCanada
PMS-docetaxelKit; Solution80 mgIntravenousPharmascience IncNot applicableNot applicableCanada
TaxotereSolution20 mgIntravenousSanofi Aventis Canada Inc1995-12-31Not applicableCanada
TaxotereInjection, solution, concentrate80 mg/4mlIntravenousAventis Pharma S.A.1995-11-27Not applicableEu
TaxotereSolution80 mgIntravenousSanofi Aventis Canada Inc1995-12-31Not applicableCanada
TaxotereInjection, solution, concentrate20 mg/0.5mlIntravenousAventis Pharma S.A.1995-11-27Not applicableEu
TaxotereInjection, solution, concentrate160 mg/8mlIntravenousAventis Pharma S.A.1995-11-27Not applicableEu
TaxotereInjection, solution, concentrate20 mg/mLIntravenousSanofi Aventis U.S. Llc2010-08-02Not applicableUs
TaxotereInjection, solution, concentrate80 mg/2mlIntravenousAventis Pharma S.A.1995-11-27Not applicableEu
TaxotereInjection, solution, concentrate80 mg/4mLIntravenousSanofi Aventis U.S. Llc2010-08-02Not applicableUs
TaxotereInjection, solution, concentrate20 mg/1mlIntravenousAventis Pharma S.A.1995-11-27Not applicableEu
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DocetaxelInjection, solution, concentrate20 mg/mLIntravenousTeva Parenteral Medicines, Inc.2015-12-31Not applicableUs
DocetaxelInjection, solution20 mg/mLIntravenousDr. Reddy's Laboratories Inc.2014-11-10Not applicableUs
DocetaxelInjection, solution, concentrate80 mg/4mLIntravenousTeva Parenteral Medicines, Inc.2015-12-31Not applicableUs
DocetaxelSolution20 mg/mLIntravenousSagent Pharmaceuticals2013-07-01Not applicableUs
DocetaxelInjection, solution20 mg/mLIntravenousDr. Reddy's Laboratories Inc.2014-11-10Not applicableUs
Docetaxel AccordInjection, solution, concentrate80 mg/4mlIntravenousAccord Healthcare Ltd2012-05-22Not applicableEu
Docetaxel AccordInjection, solution, concentrate160 mg/8mlIntravenousAccord Healthcare Ltd2012-05-22Not applicableEu
Docetaxel AccordInjection, solution, concentrate20 mg/1mlIntravenousAccord Healthcare Ltd2012-05-22Not applicableEu
Docetaxel KabiInjection, solution, concentrate160 mg/8mlIntravenousFresenius Kabi Oncology Plc2012-05-22Not applicableEu
Docetaxel KabiInjection, solution, concentrate180 mg/9mlIntravenousFresenius Kabi Oncology Plc2012-05-22Not applicableEu
Docetaxel KabiInjection, solution, concentrate80 mg/4mlIntravenousFresenius Kabi Oncology Plc2012-05-22Not applicableEu
Docetaxel KabiInjection, solution, concentrate20 mg/1mlIntravenousFresenius Kabi Oncology Plc2012-05-22Not applicableEu
Docetaxel KabiInjection, solution, concentrate120 mg/6mlIntravenousFresenius Kabi Oncology Plc2012-05-22Not applicableEu
TaxespiraInjection, solution, concentrate120 mg/6mlIntravenousHospira Uk Limited2015-08-28Not applicableEu
TaxespiraInjection, solution, concentrate140 mg/7mlIntravenousHospira Uk Limited2015-08-28Not applicableEu
TaxespiraInjection, solution, concentrate160 mg/8mlIntravenousHospira Uk Limited2015-08-28Not applicableEu
TaxespiraInjection, solution, concentrate20 mg/1mlIntravenousHospira Uk Limited2015-08-28Not applicableEu
TaxespiraInjection, solution, concentrate80 mg/4mlIntravenousHospira Uk Limited2015-08-28Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Docetaxel MylanInjection, solution, concentrate200 mg/10mlIntravenousMylan S.A.S.2012-01-31Not applicableEu
Docetaxel MylanInjection, solution, concentrate80 mg/4mlIntravenousMylan S.A.S.2012-01-31Not applicableEu
Docetaxel MylanInjection, solution, concentrate80 mg/4mlIntravenousMylan S.A.S.2012-01-31Not applicableEu
Docetaxel MylanInjection, solution, concentrate20 mg/1mlIntravenousMylan S.A.S.2012-01-31Not applicableEu
Docetaxel MylanInjection, solution, concentrate200 mg/10mlIntravenousMylan S.A.S.2012-01-31Not applicableEu
Docetaxel MylanInjection, solution, concentrate20 mg/1mlIntravenousMylan S.A.S.2012-01-31Not applicableEu
Docetaxel Teva PharmaInjection, solution, concentrate20 mgIntravenousTeva Pharma B.V.2011-01-21Not applicableEu
Docetaxel Teva PharmaInjection, solution, concentrate80 mgIntravenousTeva Pharma B.V.2011-01-21Not applicableEu
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Docetaxel trihydrate
148408-66-6
Thumb
  • InChI Key: XCDIRYDKECHIPE-QHEQPUDQSA-N
  • Monoisotopic Mass: 861.378299444
  • Average Mass: 861.935
DBSALT001786
Categories
UNII699121PHCA
CAS number114977-28-5
WeightAverage: 807.8792
Monoisotopic: 807.346605409
Chemical FormulaC43H53NO14
InChI KeyZDZOTLJHXYCWBA-VCVYQWHSSA-N
InChI
InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1
IUPAC Name
(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1,9,12-trihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0³,¹⁰.0⁴,⁷]heptadec-13-en-2-yl benzoate
SMILES
[H][C@@]12C[[email protected]](O)[C@@]3(C)C(=O)[[email protected]](O)C4=C(C)[[email protected]](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[[email protected]](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1
Pharmacology
IndicationFor the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. It is also used in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Furthermore, docetaxel has uses in the treatment of gastric adenocarinoma and head and neck cancer.
Structured Indications
PharmacodynamicsDocetaxel is a taxoid antineoplastic agent. It promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, docetaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.
Mechanism of actionDocetaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, docetaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, docetaxel binds to the β-subunit of tubulin. Tubulin is the "building block" of mictotubules, and the binding of docetaxel locks these building blocks in place. The resulting microtubule/docetaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that docetaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function.
TargetKindPharmacological actionActionsOrganismUniProt ID
Tubulin beta-1 chainProteinyesNot AvailableHumanQ9H4B7 details
Apoptosis regulator Bcl-2ProteinunknownNot AvailableHumanP10415 details
Microtubule-associated protein 2ProteinyesNot AvailableHumanP11137 details
Microtubule-associated protein 4ProteinyesNot AvailableHumanP27816 details
Microtubule-associated protein tauProteinyesNot AvailableHumanP10636 details
Nuclear receptor subfamily 1 group I member 2Proteinunknown
binder
HumanO75469 details
Related Articles
AbsorptionThe pharmacokinetic profile is consistent with a three-compartment model. The area under the curve (AUC) was dose proportional following doses of 70 mg/m2 to 115 mg/m2 with infusion times of 1 to 2 hours.
Volume of distribution

The initial rapid decline represents distribution to the peripheral compartments and the late (terminal) phase is due, in part, to a relatively slow efflux of docetaxel from the peripheral compartment.

  • 113 L
Protein bindingIn vitro studies show that 94% protein bound, mainly to a1-acid glycoprotein, albumin, and lipoproteins. When measured in cancer patients, docetaxel is 97% bound to plasma protein. Dexamethasone does not affect the protein binding of docetaxel.
Metabolism

Hepatic. In vitro drug interaction studies revealed that docetaxel is metabolized by the CYP3A4 isoenzyme (1 major, 3 minor metabolites).

Route of eliminationDocetaxel was eliminated in both the urine and feces following oxidative metabolism of the tert-butyl ester group, but fecal excretion was the main elimination route. Within 7 days, urinary and fecal excretion accounted for approximately 6% and 75% of the administered radioactivity, respectively.
Half lifeDose-dependent. Doses of 70 mg per square meter of body surface area (mg/m 2 ) or higher produce a triphasic elimination profile. With lower doses, assay limitations precluded detection of the terminal elimination phase. The half-life of the alpha, beta, and gamma phase are 4 minutes, 36 minutes, and 11.1 hours, respectively.
Clearance
  • 21 L/h/m2 [Total body clearance, cancer patients after IV administration of 20–115 mg/m2]
ToxicityOral LD50 in rat is >2000 mg/kg. Anticipated complications of overdosage include: bone marrow suppression, peripheral neurotoxicity, and mucositis. In two reports of overdose, one patient received 150 mg/m2 and the other received 200 mg/m2 as 1-hour infusions. Both patients experienced severe neutropenia, mild asthenia, cutaneous reactions, and mild paresthesia, and recovered without incident.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Docetaxel Action PathwayDrug actionSMP00435
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Canalicular multispecific organic anion transporter 1
Gene symbol: ABCC2
UniProt: Q92887
rs12762549 Not AvailableG AlleleLeukopenia, neutropenia18294295
Interactions
Drug Interactions
DrugInteractionDrug group
2-(4-Chlorophenyl)-5-QuinoxalinecarboxamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.Experimental
2-HYDROXY-1,4-NAPHTHOQUINONEThe metabolism of Docetaxel can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Experimental
2-mercaptobenzothiazoleThe metabolism of Docetaxel can be decreased when combined with 2-mercaptobenzothiazole.Vet Approved
2-MethoxyestradiolThe risk or severity of adverse effects can be increased when Docetaxel is combined with 2-Methoxyestradiol.Investigational
3-MethoxybenzamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with 3-Methoxybenzamide.Experimental
3,4-Dihydroxybenzoic AcidThe risk or severity of adverse effects can be increased when Docetaxel is combined with 3,4-Dihydroxybenzoic Acid.Experimental
5,10-Dideazatetrahydrofolic AcidThe risk or severity of adverse effects can be increased when Docetaxel is combined with 5,10-Dideazatetrahydrofolic Acid.Experimental
7-HydroxystaurosporineThe risk or severity of adverse effects can be increased when Docetaxel is combined with 7-Hydroxystaurosporine.Experimental
8-azaguanineThe risk or severity of adverse effects can be increased when Docetaxel is combined with 8-azaguanine.Experimental
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurineThe risk or severity of adverse effects can be increased when Docetaxel is combined with 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine.Investigational
AbirateroneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Abiraterone.Approved
ABT-263The risk or severity of adverse effects can be increased when Docetaxel is combined with ABT-263.Investigational
AcetaminophenThe serum concentration of Docetaxel can be increased when it is combined with Acetaminophen.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Docetaxel.Approved
AclarubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Aclarubicin.Investigational
ActeosideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Acteoside.Investigational
AfatinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Afatinib.Approved
AfimoxifeneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Afimoxifene.Investigational
AfliberceptThe risk or severity of adverse effects can be increased when Docetaxel is combined with Aflibercept.Approved
AlatrofloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Alatrofloxacin.Withdrawn
AlbendazoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Aldesleukin.Approved
AldosteroneThe serum concentration of Docetaxel can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Docetaxel can be increased when it is combined with Alectinib.Approved
AlemtuzumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Alemtuzumab.Approved, Investigational
AlfentanilThe serum concentration of Docetaxel can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Alitretinoin.Approved, Investigational
Alpha-DifluoromethylornithineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Alpha-Difluoromethylornithine.Experimental
ALT-110The risk or severity of adverse effects can be increased when Docetaxel is combined with ALT-110.Investigational
AltretamineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Altretamine.Approved
AmantadineThe serum concentration of Docetaxel can be increased when it is combined with Amantadine.Approved
Amg 386The risk or severity of adverse effects can be increased when Docetaxel is combined with Amg 386.Investigational
AminocamptothecinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Aminocamptothecin.Investigational
AminoglutethimideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Aminoglutethimide.Approved
Aminohippuric acidThe serum concentration of Docetaxel can be increased when it is combined with Aminohippuric acid.Approved
Aminolevulinic acidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Aminolevulinic acid.Approved
AmiodaroneThe metabolism of Docetaxel can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Docetaxel can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Docetaxel can be increased when it is combined with Amlodipine.Approved
AmonafideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Amonafide.Investigational
AmorolfineThe metabolism of Docetaxel can be decreased when combined with Amorolfine.Approved
Amphotericin BThe metabolism of Docetaxel can be decreased when combined with Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Docetaxel can be decreased when it is combined with Amprenavir.Approved
AmrubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Amrubicin.Approved, Investigational
AmsacrineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Amsacrine.Approved
AN2690The metabolism of Docetaxel can be decreased when combined with AN2690.Investigational
AnagrelideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Anagrelide.Approved
AnastrozoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Anastrozole.Approved, Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Docetaxel is combined with Anecortave.Investigational
AnidulafunginThe metabolism of Docetaxel can be decreased when combined with Anidulafungin.Approved, Investigational
annamycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with annamycin.Investigational
AnvirzelAnvirzel may decrease the cardiotoxic activities of Docetaxel.Investigational
AP 12009The risk or severity of adverse effects can be increased when Docetaxel is combined with AP 12009.Investigational
AP24534The risk or severity of adverse effects can be increased when Docetaxel is combined with AP24534.Investigational
ApaziquoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Apaziquone.Investigational
AprepitantThe serum concentration of Docetaxel can be increased when it is combined with Aprepitant.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Docetaxel can be decreased when combined with Artemether.Approved
ASA404The risk or severity of adverse effects can be increased when Docetaxel is combined with ASA404.Investigational
AsparaginaseThe risk or severity of adverse effects can be increased when Docetaxel is combined with Asparaginase.Approved
AstemizoleThe serum concentration of Docetaxel can be increased when it is combined with Astemizole.Approved, Withdrawn
AT-101The risk or severity of adverse effects can be increased when Docetaxel is combined with AT-101.Investigational
AtazanavirThe metabolism of Docetaxel can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Docetaxel can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Docetaxel can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Docetaxel can be increased when it is combined with Atorvastatin.Approved
AxitinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Axitinib.Approved, Investigational
AzacitidineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Azacitidine.Approved, Investigational
AzathioprineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Azathioprine.Approved
AZD2171The risk or severity of adverse effects can be increased when Docetaxel is combined with AZD2171.Investigational
Azd4547The risk or severity of adverse effects can be increased when Docetaxel is combined with Azd4547.Investigational
Azelaic AcidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Azelaic Acid.Approved
AzelastineThe serum concentration of Docetaxel can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Docetaxel can be increased when it is combined with Azithromycin.Approved
Bafilomycin A1The metabolism of Docetaxel can be decreased when combined with Bafilomycin A1.Experimental
BatimastatThe risk or severity of adverse effects can be increased when Docetaxel is combined with Batimastat.Experimental
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Docetaxel.Investigational
BelinostatThe risk or severity of adverse effects can be increased when Docetaxel is combined with Belinostat.Approved, Investigational
BelotecanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Belotecan.Investigational
BendamustineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bendamustine.Approved, Investigational
BenzocaineThe serum concentration of Docetaxel can be increased when it is combined with Benzocaine.Approved
Benzoic AcidThe metabolism of Docetaxel can be decreased when combined with Benzoic Acid.Approved
BepridilThe serum concentration of Docetaxel can be increased when it is combined with Bepridil.Approved, Withdrawn
BesifloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Besifloxacin.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Betulinic Acid.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Docetaxel.Approved, Investigational
BexaroteneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bexarotene.Approved, Investigational
Bgj398The risk or severity of adverse effects can be increased when Docetaxel is combined with Bgj398.Investigational
BicalutamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bicalutamide.Approved
BifonazoleThe metabolism of Docetaxel can be decreased when combined with Bifonazole.Approved
BiperidenThe serum concentration of Docetaxel can be increased when it is combined with Biperiden.Approved
BizelesinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bizelesin.Investigational
BleomycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bleomycin.Approved
BlinatumomabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Blinatumomab.Approved
Bmn 673The risk or severity of adverse effects can be increased when Docetaxel is combined with Bmn 673.Investigational
BoceprevirThe metabolism of Docetaxel can be decreased when combined with Boceprevir.Approved
BortezomibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Docetaxel can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bosutinib.Approved
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Brentuximab vedotin.Approved
BromocriptineThe serum concentration of Docetaxel can be increased when it is combined with Bromocriptine.Approved, Investigational
BroxuridineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Broxuridine.Investigational
Bryostatin 1The risk or severity of adverse effects can be increased when Docetaxel is combined with Bryostatin 1.Investigational
BSI-201The risk or severity of adverse effects can be increased when Docetaxel is combined with BSI-201.Investigational
BuprenorphineThe serum concentration of Docetaxel can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Docetaxel can be increased when it is combined with Buspirone.Approved, Investigational
BusulfanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Busulfan.Approved, Investigational
ButenafineThe metabolism of Docetaxel can be decreased when combined with Butenafine.Approved
Buthionine SulfoximineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Buthionine Sulfoximine.Investigational
ButoconazoleThe metabolism of Docetaxel can be decreased when combined with Butoconazole.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cabazitaxel.Approved
CabergolineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cabergoline.Approved
CabozantinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cabozantinib.Approved
CaffeineThe serum concentration of Docetaxel can be increased when it is combined with Caffeine.Approved
CaiThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cai.Investigational
CalcipotriolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Calcipotriol.Approved
CamptothecinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Camptothecin.Experimental
CanagliflozinThe serum concentration of Docetaxel can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Docetaxel can be increased when it is combined with Candesartan.Approved
CandicidinThe metabolism of Docetaxel can be decreased when combined with Candicidin.Withdrawn
CapecitabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Docetaxel can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Docetaxel can be increased when combined with Carbamazepine.Approved, Investigational
CarboplatinCarboplatin may increase the myelosuppressive activities of Docetaxel.Approved
CarfilzomibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Carfilzomib.Approved
CarmofurThe risk or severity of adverse effects can be increased when Docetaxel is combined with Carmofur.Withdrawn
CarmustineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Carmustine.Approved
CarvedilolThe serum concentration of Docetaxel can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe metabolism of Docetaxel can be decreased when combined with Caspofungin.Approved
CatumaxomabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Catumaxomab.Investigational
CB1954The risk or severity of adverse effects can be increased when Docetaxel is combined with CB1954.Experimental
CDX-110The risk or severity of adverse effects can be increased when Docetaxel is combined with CDX-110.Investigational
CediranibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cediranib.Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Docetaxel can be increased when it is combined with Ceritinib.Approved
CeruleninThe metabolism of Docetaxel can be decreased when combined with Cerulenin.Approved
CetuximabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cetuximab.Approved
ChlorambucilThe risk or severity of adverse effects can be increased when Docetaxel is combined with Chlorambucil.Approved
ChloroquineThe serum concentration of Docetaxel can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorotrianiseneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Chlorotrianisene.Withdrawn
ChloroxineThe metabolism of Docetaxel can be decreased when combined with Chloroxine.Approved
ChlorpromazineThe serum concentration of Docetaxel can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Docetaxel can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Docetaxel can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Docetaxel can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Docetaxel can be decreased when it is combined with Cholic Acid.Approved
CiclopiroxThe metabolism of Docetaxel can be decreased when combined with Ciclopirox.Approved, Investigational
CilazaprilThe serum concentration of Docetaxel can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Docetaxel can be decreased when it is combined with Cimetidine.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ciprofloxacin.Approved, Investigational
CisplatinCisplatin may increase the myelosuppressive activities of Docetaxel.Approved
CitalopramThe serum concentration of Docetaxel can be increased when it is combined with Citalopram.Approved
CladribineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cladribine.Approved, Investigational
ClarithromycinThe metabolism of Docetaxel can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Docetaxel can be decreased when combined with Clemastine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Docetaxel can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Docetaxel can be increased when it is combined with Clomipramine.Approved, Vet Approved
clorarabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with clorarabine.Investigational
ClotrimazoleThe metabolism of Docetaxel can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Clozapine.Approved
CobicistatThe metabolism of Docetaxel can be decreased when combined with Cobicistat.Approved
ColchicineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Colchicine.Approved
ColforsinThe serum concentration of Docetaxel can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Docetaxel can be increased when it is combined with Conivaptan.Approved, Investigational
CordycepinThe metabolism of Docetaxel can be decreased when combined with Cordycepin.Investigational
CrenolanibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Crenolanib.Investigational
CrizotinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Docetaxel is combined with Curcumin.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Docetaxel.Approved, Investigational
CyclosporineThe metabolism of Docetaxel can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cytarabine.Approved, Investigational
DabrafenibThe serum concentration of Docetaxel can be decreased when it is combined with Dabrafenib.Approved
DacarbazineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dacarbazine.Approved, Investigational
DaclatasvirThe serum concentration of Docetaxel can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dactinomycin.Approved
DaratumumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Daratumumab.Approved
DarunavirThe metabolism of Docetaxel can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Docetaxel can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Daunorubicin.Approved
Decanoic AcidThe metabolism of Docetaxel can be decreased when combined with Decanoic Acid.Experimental
DecitabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Decitabine.Approved, Investigational
DeferasiroxThe serum concentration of Docetaxel can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Docetaxel can be decreased when combined with Delavirdine.Approved
Denileukin diftitoxThe risk or severity of adverse effects can be increased when Docetaxel is combined with Denileukin diftitox.Approved, Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Docetaxel.Approved
DeoxyspergualinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Deoxyspergualin.Investigational
DesipramineThe serum concentration of Docetaxel can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Docetaxel.Approved
DesloratadineThe serum concentration of Docetaxel can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexrazoxaneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dexrazoxane.Approved, Withdrawn
DextromethorphanThe serum concentration of Docetaxel can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Docetaxel can be increased when it is combined with Diclofenac.Approved, Vet Approved
DienogestThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dienogest.Approved
DiethylstilbestrolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Diethylstilbestrol.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Docetaxel.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Docetaxel.Approved
DihydroergotamineThe metabolism of Docetaxel can be decreased when combined with Dihydroergotamine.Approved
DiindolylmethaneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Diindolylmethane.Investigational
DiltiazemThe metabolism of Docetaxel can be decreased when combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dinutuximab.Approved
DipyridamoleThe serum concentration of Docetaxel can be increased when it is combined with Dipyridamole.Approved
DoxazosinThe serum concentration of Docetaxel can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Docetaxel can be increased when it is combined with Doxepin.Approved
DoxifluridineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Doxifluridine.Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Docetaxel.Approved, Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Docetaxel can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Docetaxel can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Docetaxel can be increased when it is combined with Dronedarone.Approved
EcabetThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ecabet.Approved, Investigational
EconazoleThe metabolism of Docetaxel can be decreased when combined with Econazole.Approved
efaproxiralThe risk or severity of adverse effects can be increased when Docetaxel is combined with efaproxiral.Investigational
EfavirenzThe serum concentration of Docetaxel can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe metabolism of Docetaxel can be decreased when combined with Efinaconazole.Approved
EflornithineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Eflornithine.Approved, Withdrawn
EG009The risk or severity of adverse effects can be increased when Docetaxel is combined with EG009.Investigational
ElbasvirThe serum concentration of Docetaxel can be increased when it is combined with Elbasvir.Approved
ElsamitrucinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Elsamitrucin.Investigational
EltrombopagThe serum concentration of Docetaxel can be increased when it is combined with Eltrombopag.Approved
EnalaprilThe serum concentration of Docetaxel can be increased when it is combined with Enalapril.Approved, Vet Approved
EndostatinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Endostatin.Investigational
EnoxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Enoxacin.Approved
EnrofloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Enrofloxacin.Vet Approved
EntinostatThe risk or severity of adverse effects can be increased when Docetaxel is combined with Entinostat.Investigational
EnzalutamideThe serum concentration of Docetaxel can be decreased when it is combined with Enzalutamide.Approved
EpirubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Epirubicin.Approved
EpofolateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Epofolate.Investigational
Epothilone BThe risk or severity of adverse effects can be increased when Docetaxel is combined with Epothilone B.Experimental, Investigational
ErgonovineThe serum concentration of Docetaxel can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Docetaxel can be increased when it is combined with Ergotamine.Approved
EribulinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Eribulin.Approved, Investigational
ErlotinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Erlotinib.Approved, Investigational
ErythromycinThe metabolism of Docetaxel can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Docetaxel can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstramustineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Estramustine.Approved
EstriolThe serum concentration of Docetaxel can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Docetaxel can be decreased when it is combined with Estrone.Approved
EtanidazoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Etanidazole.Investigational
Ethiodized oilThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ethiodized oil.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ethyl carbamate.Withdrawn
EtoposideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Etoposide.Approved
EtravirineThe serum concentration of Docetaxel can be decreased when it is combined with Etravirine.Approved
EverolimusThe risk or severity of adverse effects can be increased when Docetaxel is combined with Everolimus.Approved
ExatecanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Exatecan.Investigational
ExemestaneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Exemestane.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when Docetaxel is combined with exisulind.Investigational
FelodipineThe serum concentration of Docetaxel can be increased when it is combined with Felodipine.Approved, Investigational
FenretinideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fenretinide.Investigational
FentanylThe serum concentration of Docetaxel can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Docetaxel can be increased when it is combined with Fexofenadine.Approved
FiacitabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fiacitabine.Investigational
FidaxomicinThe serum concentration of Docetaxel can be increased when it is combined with Fidaxomicin.Approved
FingolimodDocetaxel may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FlavopiridolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Flavopiridol.Experimental, Investigational
FleroxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fleroxacin.Approved
FloxuridineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Floxuridine.Approved
FluconazoleThe metabolism of Docetaxel can be decreased when combined with Fluconazole.Approved
FlucytosineThe metabolism of Docetaxel can be decreased when combined with Flucytosine.Approved
FludarabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fludarabine.Approved
FlumequineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Flumequine.Withdrawn
FluorouracilThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fluorouracil.Approved
FluoxetineThe serum concentration of Docetaxel can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Docetaxel can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Docetaxel can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Docetaxel can be increased when it is combined with Flurazepam.Approved, Illicit
FlutamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Flutamide.Approved
FluvoxamineThe metabolism of Docetaxel can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Formestane.Approved, Investigational, Withdrawn
FormycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Formycin.Experimental
FosamprenavirThe metabolism of Docetaxel can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Docetaxel can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Docetaxel can be increased when combined with Fosphenytoin.Approved
FotemustineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fotemustine.Experimental
FulvestrantThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fulvestrant.Approved, Investigational
FumagillinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fumagillin.Experimental
Fusidic AcidThe serum concentration of Docetaxel can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Docetaxel is combined with G17DT.Investigational
Gallium nitrateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gallium nitrate.Approved, Investigational
GarenoxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gatifloxacin.Approved, Investigational
GefitinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gefitinib.Approved, Investigational
GeldanamycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Geldanamycin.Experimental
GemcitabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gemcitabine.Approved
GemifloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gemifloxacin.Approved, Investigational
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gemtuzumab ozogamicin.Approved, Investigational, Withdrawn
GenisteinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Docetaxel is combined with GI-5005.Investigational
Ginsenoside CThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ginsenoside C.Nutraceutical
GlyburideThe serum concentration of Docetaxel can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Docetaxel can be increased when it is combined with Glycerol.Experimental
GlyphosateThe metabolism of Docetaxel can be decreased when combined with Glyphosate.Experimental
GoserelinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Goserelin.Approved
Gramicidin DThe serum concentration of Docetaxel can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Grepafloxacin.Withdrawn
GriseofulvinThe metabolism of Docetaxel can be decreased when combined with Griseofulvin.Approved, Vet Approved
GusperimusThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gusperimus.Investigational
HadacidinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Hadacidin.Experimental
HalofuginoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Halofuginone.Investigational, Vet Approved
HaloperidolThe serum concentration of Docetaxel can be increased when it is combined with Haloperidol.Approved
HaloproginThe metabolism of Docetaxel can be decreased when combined with Haloprogin.Approved, Withdrawn
HexestrolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Hexestrol.Withdrawn
HexetidineThe metabolism of Docetaxel can be decreased when combined with Hexetidine.Approved
HydrocortisoneThe serum concentration of Docetaxel can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
Hydroxyprogesterone caproateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Hydroxyprogesterone caproate.Approved
HydroxyureaThe risk or severity of adverse effects can be increased when Docetaxel is combined with Hydroxyurea.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ibrutinib.Approved
IdarubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Idarubicin.Approved
IdelalisibThe serum concentration of Docetaxel can be increased when it is combined with Idelalisib.Approved
IfosfamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ifosfamide.Approved
Il 4The risk or severity of adverse effects can be increased when Docetaxel is combined with Il 4.Investigational
ImatinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Imatinib.Approved
ImipramineThe serum concentration of Docetaxel can be increased when it is combined with Imipramine.Approved
ImiquimodThe risk or severity of adverse effects can be increased when Docetaxel is combined with Imiquimod.Approved, Investigational
IndinavirThe metabolism of Docetaxel can be decreased when combined with Indinavir.Approved
IndirubinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Indirubin.Investigational
IndomethacinThe serum concentration of Docetaxel can be increased when it is combined with Indomethacin.Approved, Investigational
INGN 201The risk or severity of adverse effects can be increased when Docetaxel is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Docetaxel is combined with INGN 225.Investigational
Interferon beta-1aThe risk or severity of adverse effects can be increased when Docetaxel is combined with Interferon beta-1a.Approved, Investigational
Interferon beta-1bThe risk or severity of adverse effects can be increased when Docetaxel is combined with Interferon beta-1b.Approved
IobenguaneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Iobenguane.Approved
IpilimumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ipilimumab.Approved
IrinotecanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Irinotecan.Approved, Investigational
IrofulvenThe risk or severity of adverse effects can be increased when Docetaxel is combined with Irofulven.Investigational
IsavuconazoniumThe metabolism of Docetaxel can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoconazoleThe metabolism of Docetaxel can be decreased when combined with Isoconazole.Approved
IsradipineThe metabolism of Docetaxel can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Docetaxel can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Docetaxel can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Docetaxel can be increased when it is combined with Ivermectin.Approved, Vet Approved
IxabepiloneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ixabepilone.Approved, Investigational
IxazomibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ixazomib.Approved
KetamineThe serum concentration of Docetaxel can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe metabolism of Docetaxel can be decreased when combined with Ketoconazole.Approved, Investigational
KOS-1584The risk or severity of adverse effects can be increased when Docetaxel is combined with KOS-1584.Investigational
L-alanosineThe risk or severity of adverse effects can be increased when Docetaxel is combined with L-alanosine.Investigational
LanreotideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lanreotide.Approved
LansoprazoleThe serum concentration of Docetaxel can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lapatinib.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Leflunomide.Approved, Investigational
LenalidomideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lenalidomide.Approved
LenvatinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lenvatinib.Approved
LetrozoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Letrozole.Approved, Investigational
LeuprolideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Leuprolide.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Docetaxel can be decreased when it is combined with Levothyroxine.Approved
LiarozoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Liarozole.Investigational
LidocaineThe serum concentration of Docetaxel can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Docetaxel can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Docetaxel can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Docetaxel can be increased when it is combined with Lisinopril.Approved, Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lomefloxacin.Approved
LomitapideThe serum concentration of Docetaxel can be increased when it is combined with Lomitapide.Approved
LomustineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lomustine.Approved
LonidamineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lonidamine.Approved, Investigational
LoperamideThe serum concentration of Docetaxel can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Docetaxel can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Docetaxel can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Docetaxel can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Docetaxel can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Docetaxel can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Docetaxel can be decreased when it is combined with Lumacaftor.Approved
Ly2801653The risk or severity of adverse effects can be increased when Docetaxel is combined with Ly2801653.Investigational
LycopeneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lycopene.Approved
MafosfamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mafosfamide.Investigational
MaprotilineThe serum concentration of Docetaxel can be increased when it is combined with Maprotiline.Approved
MasitinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Masitinib.Vet Approved
MasoprocolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Masoprocol.Approved
MaxacalcitolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Maxacalcitol.Approved
MDX-1106The risk or severity of adverse effects can be increased when Docetaxel is combined with MDX-1106.Investigational
MebendazoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mebendazole.Approved, Vet Approved
MechlorethamineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mechlorethamine.Approved
MedrogestoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Medrogestone.Approved
Medroxyprogesterone acetateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Medroxyprogesterone acetate.Approved, Investigational
MefloquineThe serum concentration of Docetaxel can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Megestrol acetate.Approved, Vet Approved
MelphalanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Melphalan.Approved
MeprobamateThe serum concentration of Docetaxel can be increased when it is combined with Meprobamate.Approved, Illicit
MequinolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mequinol.Approved
MercaptopurineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mercaptopurine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Docetaxel.Withdrawn
MethadoneThe serum concentration of Docetaxel can be increased when it is combined with Methadone.Approved
MethotrexateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Methotrexate.Approved
Methyl aminolevulinateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Methyl aminolevulinate.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Methylprednisolone.Approved, Vet Approved
MethyltestosteroneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Methyltestosterone.Approved
MetoprololThe serum concentration of Docetaxel can be increased when it is combined with Metoprolol.Approved, Investigational
MevastatinThe metabolism of Docetaxel can be decreased when combined with Mevastatin.Experimental
MGI-114The risk or severity of adverse effects can be increased when Docetaxel is combined with MGI-114.Investigational
MibefradilThe serum concentration of Docetaxel can be increased when it is combined with Mibefradil.Withdrawn
MicafunginThe metabolism of Docetaxel can be decreased when combined with Micafungin.Approved, Investigational
MiconazoleThe metabolism of Docetaxel can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Docetaxel can be decreased when it is combined with Midazolam.Approved, Illicit
MidostaurinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Midostaurin.Investigational
MifepristoneThe serum concentration of Docetaxel can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe metabolism of Docetaxel can be decreased when combined with Miltefosine.Approved
MisonidazoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Misonidazole.Investigational
MitoguazoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mitoguazone.Investigational
MitolactolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mitolactol.Investigational
MitomycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mitomycin.Approved
MitotaneThe serum concentration of Docetaxel can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mitoxantrone.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mizoribine.Investigational
MLN576The risk or severity of adverse effects can be increased when Docetaxel is combined with MLN576.Investigational
ModafinilThe serum concentration of Docetaxel can be decreased when it is combined with Modafinil.Approved, Investigational
MolgramostimThe risk or severity of adverse effects can be increased when Docetaxel is combined with Molgramostim.Investigational
MonensinThe metabolism of Docetaxel can be decreased when combined with Monensin.Vet Approved
MorphineThe serum concentration of Docetaxel can be increased when it is combined with Morphine.Approved, Investigational
motexafin gadoliniumThe risk or severity of adverse effects can be increased when Docetaxel is combined with motexafin gadolinium.Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Moxifloxacin.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mycophenolic acid.Approved
MyxothiazolThe metabolism of Docetaxel can be decreased when combined with Myxothiazol.Experimental
NafcillinThe serum concentration of Docetaxel can be decreased when it is combined with Nafcillin.Approved
NaftifineThe metabolism of Docetaxel can be decreased when combined with Naftifine.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nalidixic Acid.Approved
NaltrexoneThe serum concentration of Docetaxel can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NamitecanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Namitecan.Investigational
NaringeninThe serum concentration of Docetaxel can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Natalizumab.Approved, Investigational
NatamycinThe metabolism of Docetaxel can be decreased when combined with Natamycin.Approved
NavitoclaxThe risk or severity of adverse effects can be increased when Docetaxel is combined with Navitoclax.Investigational
NecitumumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Necitumumab.Approved
NedaplatinNedaplatin may increase the myelosuppressive activities of Docetaxel.Approved
NefazodoneThe metabolism of Docetaxel can be decreased when combined with Nefazodone.Approved, Withdrawn
NelarabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nelarabine.Approved, Investigational
NelfinavirThe metabolism of Docetaxel can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Docetaxel can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Docetaxel can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Docetaxel can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Docetaxel can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Docetaxel can be decreased when it is combined with Nifedipine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Niguldipine.Experimental
NilotinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nilotinib.Approved, Investigational
NilutamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nilutamide.Approved
NimustineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nimustine.Investigational
NintedanibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nintedanib.Approved
NisoldipineThe serum concentration of Docetaxel can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Docetaxel can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Docetaxel can be increased when it is combined with Nitrendipine.Approved
NitroxolineThe metabolism of Docetaxel can be decreased when combined with Nitroxoline.Approved
NivolumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nivolumab.Approved
Nk012The risk or severity of adverse effects can be increased when Docetaxel is combined with Nk012.Investigational
nocodazoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with nocodazole.Experimental
NolatrexedThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nolatrexed.Investigational
NorethisteroneThe serum concentration of Docetaxel can be decreased when it is combined with Norethisterone.Approved
NorfloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Norfloxacin.Approved
NOV-002NOV-002 may increase the myelosuppressive activities of Docetaxel.Investigational
NystatinThe metabolism of Docetaxel can be decreased when combined with Nystatin.Approved, Vet Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Obinutuzumab.Approved
OctreotideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Octreotide.Approved, Investigational
OfatumumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ofatumumab.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ofloxacin.Approved
OlaparibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Olaparib.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Omacetaxine mepesuccinate.Approved
OmeprazoleThe serum concentration of Docetaxel can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OprelvekinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Oprelvekin.Approved, Investigational
OsimertinibThe serum concentration of Docetaxel can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Docetaxel.Approved
OxaliplatinOxaliplatin may increase the myelosuppressive activities of Docetaxel.Approved, Investigational
OxiconazoleThe metabolism of Docetaxel can be decreased when combined with Oxiconazole.Approved
P-NitrophenolThe serum concentration of Docetaxel can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Docetaxel.Approved, Vet Approved
pafuramidineThe metabolism of Docetaxel can be decreased when combined with pafuramidine.Investigational
PalbociclibThe serum concentration of Docetaxel can be increased when it is combined with Palbociclib.Approved
PalifosfamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Palifosfamide.Investigational
Palmitic AcidThe serum concentration of Docetaxel can be increased when it is combined with Palmitic Acid.Experimental
PamidronateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pamidronate.Approved
PanitumumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Panitumumab.Approved, Investigational
PanobinostatThe risk or severity of adverse effects can be increased when Docetaxel is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Docetaxel can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Docetaxel can be increased when it is combined with Paroxetine.Approved, Investigational
PARP inhibitorThe risk or severity of adverse effects can be increased when Docetaxel is combined with PARP inhibitor.Investigational
PazopanibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pazopanib.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pefloxacin.Approved
PegaspargaseThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pegaspargase.Approved, Investigational
PembrolizumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pembrolizumab.Approved
PemetrexedThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pemetrexed.Approved, Investigational
PenclomedineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Penclomedine.Investigational
PentamidineThe metabolism of Docetaxel can be decreased when combined with Pentamidine.Approved
PentobarbitalThe metabolism of Docetaxel can be increased when combined with Pentobarbital.Approved, Vet Approved
PentostatinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pentostatin.Approved, Investigational
PerindoprilThe serum concentration of Docetaxel can be increased when it is combined with Perindopril.Approved
PertuzumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pertuzumab.Approved
PhenobarbitalThe metabolism of Docetaxel can be increased when combined with Phenobarbital.Approved
Phenylacetic acidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Phenylacetic acid.Approved
PhenytoinThe metabolism of Docetaxel can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Docetaxel.Approved, Investigational
PimozideThe serum concentration of Docetaxel can be increased when it is combined with Pimozide.Approved
PipobromanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pipobroman.Approved
PirarubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pirarubicin.Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pirfenidone.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pirlindole.Approved
PixantroneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pixantrone.Investigational
Platelet Activating FactorThe serum concentration of Docetaxel can be decreased when it is combined with Platelet Activating Factor.Experimental
PlevitrexedThe risk or severity of adverse effects can be increased when Docetaxel is combined with Plevitrexed.Investigational
PlicamycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Plicamycin.Approved, Withdrawn
PodofiloxThe risk or severity of adverse effects can be increased when Docetaxel is combined with Podofilox.Approved
PodophyllinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Podophyllin.Approved
polyacrylic acidThe risk or severity of adverse effects can be increased when Docetaxel is combined with polyacrylic acid.Investigational
PomalidomideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pomalidomide.Approved
PonatinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ponatinib.Approved
PorfimerThe risk or severity of adverse effects can be increased when Docetaxel is combined with Porfimer.Approved, Investigational
porfiromycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with porfiromycin.Investigational
PosaconazoleThe metabolism of Docetaxel can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PralatrexateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pralatrexate.Approved
PravastatinThe serum concentration of Docetaxel can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Docetaxel can be increased when it is combined with Prazosin.Approved
PrednimustineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Prednimustine.Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Prednisone.Approved, Vet Approved
PrimidoneThe metabolism of Docetaxel can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Docetaxel can be increased when it is combined with Probenecid.Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Procarbazine.Approved
ProgesteroneThe serum concentration of Docetaxel can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Docetaxel can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Docetaxel can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Docetaxel can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Docetaxel can be increased when it is combined with Protriptyline.Approved
Purine RibosideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Purine Riboside.Experimental
PuromycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Puromycin.Experimental
PyrazoloacridineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pyrazoloacridine.Investigational
Qlt091001The risk or severity of adverse effects can be increased when Docetaxel is combined with Qlt091001.Investigational
QuercetinThe serum concentration of Docetaxel can be increased when it is combined with Quercetin.Experimental
QuinacrineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Quinacrine.Approved
QuinidineThe serum concentration of Docetaxel can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Docetaxel can be increased when it is combined with Quinine.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Docetaxel.Approved
RadicicolThe metabolism of Docetaxel can be decreased when combined with Radicicol.Experimental
Radium Ra 223 DichlorideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Radium Ra 223 Dichloride.Approved, Investigational
RaltitrexedThe risk or severity of adverse effects can be increased when Docetaxel is combined with Raltitrexed.Approved, Investigational
RamucirumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ramucirumab.Approved, Investigational
RanibizumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ranibizumab.Approved
RanitidineThe serum concentration of Docetaxel can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Docetaxel can be increased when it is combined with Ranolazine.Approved, Investigational
RanpirnaseThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ranpirnase.Investigational
ReboxetineThe serum concentration of Docetaxel can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Regorafenib.Approved
ReserpineThe serum concentration of Docetaxel can be decreased when it is combined with Reserpine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Resveratrol.Experimental, Investigational
Rhodamine 6GThe risk or severity of adverse effects can be increased when Docetaxel is combined with Rhodamine 6G.Experimental
RifabutinThe metabolism of Docetaxel can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Docetaxel can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Docetaxel can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Docetaxel can be increased when it is combined with Rilpivirine.Approved
RitonavirThe metabolism of Docetaxel can be decreased when combined with Ritonavir.Approved, Investigational
RituximabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Rituximab.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Docetaxel.Approved
RolapitantThe serum concentration of Docetaxel can be increased when it is combined with Rolapitant.Approved
RomidepsinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Romidepsin.Approved, Investigational
RomiplostimThe risk or severity of adverse effects can be increased when Docetaxel is combined with Romiplostim.Approved
RoquinimexThe risk or severity of adverse effects can be increased when Docetaxel is combined with Roquinimex.Investigational
RubitecanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Rubitecan.Investigational
RucaparibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Rucaparib.Investigational
RuxolitinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ruxolitinib.Approved
Salicylhydroxamic AcidThe metabolism of Docetaxel can be decreased when combined with Salicylhydroxamic Acid.Experimental
Salicylic acidThe metabolism of Docetaxel can be decreased when combined with Salicylic acid.Approved, Vet Approved
SalirasibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Salirasib.Investigational
SaquinavirThe metabolism of Docetaxel can be decreased when combined with Saquinavir.Approved, Investigational
SaracatinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Saracatinib.Investigational
SatraplatinSatraplatin may increase the myelosuppressive activities of Docetaxel.Investigational
ScopolamineThe serum concentration of Docetaxel can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Docetaxel can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SeliciclibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Seliciclib.Investigational
SemaxanibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Semaxanib.Investigational
SeocalcitolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Seocalcitol.Experimental
SertaconazoleThe metabolism of Docetaxel can be decreased when combined with Sertaconazole.Approved
SertralineThe serum concentration of Docetaxel can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Docetaxel can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Docetaxel can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Docetaxel can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Docetaxel can be increased when it is combined with Simvastatin.Approved
SinefunginThe metabolism of Docetaxel can be decreased when combined with Sinefungin.Experimental
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Docetaxel.Approved
SirolimusThe metabolism of Docetaxel can be decreased when combined with Sirolimus.Approved, Investigational
Sodium phenylbutyrateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sodium phenylbutyrate.Approved
SonidegibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sonidegib.Approved, Investigational
SonifilanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sonifilan.Investigational
SorafenibThe serum concentration of Docetaxel can be increased when it is combined with Sorafenib.Approved, Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sparfloxacin.Approved
Sparfosic acidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sparfosic acid.Experimental
SparsomycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sparsomycin.Experimental
SpironolactoneThe serum concentration of Docetaxel can be increased when it is combined with Spironolactone.Approved
squalamineThe risk or severity of adverse effects can be increased when Docetaxel is combined with squalamine.Investigational
SRP 299The risk or severity of adverse effects can be increased when Docetaxel is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when Docetaxel is combined with SRT501.Investigational
St. John's WortThe serum concentration of Docetaxel can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Docetaxel can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Docetaxel can be increased when it is combined with Stiripentol.Approved
StreptozocinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Streptozocin.Approved
SulconazoleThe metabolism of Docetaxel can be decreased when combined with Sulconazole.Approved
SulfinpyrazoneThe serum concentration of Docetaxel can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Docetaxel can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulforaphaneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sulforaphane.Investigational
SulindacThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sulindac.Approved
SumatriptanThe serum concentration of Docetaxel can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sunitinib.Approved, Investigational
SuraminThe risk or severity of adverse effects can be increased when Docetaxel is combined with Suramin.Approved
SwainsonineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Swainsonine.Experimental
TacrineThe serum concentration of Docetaxel can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Docetaxel.Approved, Investigational
TacrolimusThe serum concentration of Docetaxel can be decreased when it is combined with Tacrolimus.Approved, Investigational
TalaporfinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Talaporfin.Investigational
TamoxifenThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Docetaxel can be increased when it is combined with Taurocholic Acid.Experimental
TavaboroleThe metabolism of Docetaxel can be decreased when combined with Tavaborole.Approved
TegafurThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tegafur.Approved
TelaprevirThe metabolism of Docetaxel can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Docetaxel can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Docetaxel can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Temafloxacin.Withdrawn
TemoporfinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Temoporfin.Approved
TemozolomideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Temozolomide.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Docetaxel is combined with Temsirolimus.Approved
TeniposideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Teniposide.Approved
TerazosinThe serum concentration of Docetaxel can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Docetaxel can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe metabolism of Docetaxel can be decreased when combined with Terconazole.Approved
TerfenadineThe serum concentration of Docetaxel can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Docetaxel can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Docetaxel can be decreased when it is combined with Tesmilifene.Investigational
TestolactoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Testolactone.Approved
TestosteroneThe serum concentration of Docetaxel can be increased when it is combined with Testosterone.Approved, Investigational
TetrathiomolybdateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tetrathiomolybdate.Investigational
TezacitabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tezacitabine.Investigational
TG4010The risk or severity of adverse effects can be increased when Docetaxel is combined with TG4010.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiotepaThe risk or severity of adverse effects can be increased when Docetaxel is combined with Thiotepa.Approved
ThymalfasinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Thymalfasin.Approved, Investigational
ThymolThe metabolism of Docetaxel can be decreased when combined with Thymol.Approved
TiboloneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tibolone.Approved
TicagrelorThe serum concentration of Docetaxel can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Docetaxel can be decreased when combined with Ticlopidine.Approved
TioconazoleThe metabolism of Docetaxel can be decreased when combined with Tioconazole.Approved
TioguanineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tioguanine.Approved
TipifarnibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tipifarnib.Investigational
TirapazamineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tirapazamine.Investigational
TivozanibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tivozanib.Investigational
Tnp 470The risk or severity of adverse effects can be increased when Docetaxel is combined with Tnp 470.Investigational
TocilizumabThe serum concentration of Docetaxel can be decreased when it is combined with Tocilizumab.Approved
TofacitinibDocetaxel may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolnaftateThe metabolism of Docetaxel can be decreased when combined with Tolnaftate.Approved, Vet Approved
TolvaptanThe serum concentration of Docetaxel can be increased when it is combined with Tolvaptan.Approved
TopotecanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Topotecan.Approved, Investigational
ToremifeneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Toremifene.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tositumomab.Approved
TrabectedinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trabectedin.Approved, Investigational
TrametinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trametinib.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Docetaxel.Approved, Investigational
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trastuzumab emtansine.Approved
TrazodoneThe serum concentration of Docetaxel can be decreased when it is combined with Trazodone.Approved, Investigational
TreosulfanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Treosulfan.Investigational
TretazicarThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tretazicar.Investigational
TretinoinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tretinoin.Approved, Investigational, Nutraceutical
TrifluoperazineThe serum concentration of Docetaxel can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Docetaxel can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrifluridineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trifluridine.Approved
TrilostaneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimethoprimThe serum concentration of Docetaxel can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimetrexateThe metabolism of Docetaxel can be decreased when combined with Trimetrexate.Approved, Investigational
TrimipramineThe serum concentration of Docetaxel can be increased when it is combined with Trimipramine.Approved
TriptorelinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Triptorelin.Approved, Vet Approved
TrofosfamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trofosfamide.Investigational
TroleandomycinThe serum concentration of Docetaxel can be increased when it is combined with Troleandomycin.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trovafloxacin.Approved, Withdrawn
TroxacitabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Troxacitabine.Investigational
TTNPBThe risk or severity of adverse effects can be increased when Docetaxel is combined with TTNPB.Experimental
TubercidinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tubercidin.Experimental
UbenimexThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ubenimex.Experimental
Uracil mustardThe risk or severity of adverse effects can be increased when Docetaxel is combined with Uracil mustard.Approved
VadimezanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vadimezan.Investigational
Val 083The risk or severity of adverse effects can be increased when Docetaxel is combined with Val 083.Investigational
ValrubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Valrubicin.Approved
VandetanibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vandetanib.Approved
VapreotideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vapreotide.Approved, Investigational
VeliparibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Veliparib.Investigational
VemurafenibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Docetaxel can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Docetaxel can be decreased when combined with Verapamil.Approved
VerteporfinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Verteporfin.Approved, Investigational
VesnarinoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vesnarinone.Investigational
VinblastineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vinblastine.Approved
VincristineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vincristine.Approved, Investigational
VindesineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vindesine.Approved
VinflunineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vinflunine.Approved
VinorelbineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vinorelbine.Approved, Investigational
VintafolideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vintafolide.Investigational
VismodegibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vismodegib.Approved
Vitamin AThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vitamin A.Approved, Nutraceutical, Vet Approved
VoriconazoleThe metabolism of Docetaxel can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vorinostat.Approved, Investigational
ZimelidineThe serum concentration of Docetaxel can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Docetaxel can be decreased when combined with Ziprasidone.Approved
ZorubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Zorubicin.Experimental
Food InteractionsNot Available
References
Synthesis Reference

Nicholas J. Sisti, Charles S. Swindell, “Method for docetaxel synthesis.” U.S. Patent US5688977, issued September, 1991.

US5688977
General ReferencesNot Available
External Links
ATC CodesL01CD02
AHFS Codes
  • 10:00.00
PDB EntriesNot Available
FDA labelDownload (140 KB)
MSDSDownload (100 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9743
Blood Brain Barrier-0.9659
Caco-2 permeable-0.8252
P-glycoprotein substrateSubstrate0.8259
P-glycoprotein inhibitor IInhibitor0.644
P-glycoprotein inhibitor IINon-inhibitor0.5139
Renal organic cation transporterNon-inhibitor0.9393
CYP450 2C9 substrateNon-substrate0.816
CYP450 2D6 substrateNon-substrate0.8828
CYP450 3A4 substrateSubstrate0.7119
CYP450 1A2 substrateNon-inhibitor0.8299
CYP450 2C9 inhibitorNon-inhibitor0.8737
CYP450 2D6 inhibitorNon-inhibitor0.8972
CYP450 2C19 inhibitorNon-inhibitor0.8421
CYP450 3A4 inhibitorNon-inhibitor0.7324
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8776
Ames testNon AMES toxic0.8382
CarcinogenicityNon-carcinogens0.9133
BiodegradationNot ready biodegradable0.9934
Rat acute toxicity2.5741 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9907
hERG inhibition (predictor II)Non-inhibitor0.7905
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Kit
Injection, solutionIntravenous10 mg/mL
Injection, solutionIntravenous20 mg/mL
Injection, solutionIntravenous80 mg/4mL
Injection, solution, concentrateIntravenous20 mg/2mL
Injection, solution, concentrateIntravenous20 mg/mL
Injection, solution, concentrateIntravenous200 mg/20mL
Injection, solution, concentrateIntravenous80 mg/4mL
Injection, solution, concentrateIntravenous80 mg/8mL
SolutionIntravenous20 mg/mL
SolutionIntravenous10.0 mg
SolutionIntravenous10 mg
Injection, solution, concentrateIntravenous120 mg/6ml
Injection, solution, concentrateIntravenous160 mg/8ml
Injection, solution, concentrateIntravenous180 mg/9ml
Injection, solution, concentrateIntravenous20 mg/1ml
Injection, solution, concentrateIntravenous200 mg/10ml
InjectionIntravenous20 mg/mL
Injection, solution, concentrateIntravenous20 mg
Injection, solution, concentrateIntravenous80 mg
Kit; solutionIntravenous20 mg
Kit; solutionIntravenous80 mg
Injection, solution, concentrateIntravenous140 mg/7ml
Injection, solution, concentrateIntravenous20 mg/0.5ml
Injection, solution, concentrateIntravenous80 mg/2ml
SolutionIntravenous20 mg
SolutionIntravenous80 mg
Prices
Unit descriptionCostUnit
Taxotere 20 mg/0.5 ml vial477.37USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2149055 No2003-01-072013-11-08Canada
CA2150576 No2005-06-212013-11-26Canada
US4814470 No1993-05-142010-05-14Us
US5438072 No1994-05-222014-05-22Us
US8940786 No2013-09-302033-09-30Us
US9308195 No2013-09-302033-09-30Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point232 °CPhysProp
water solubilityInsoluble FDA label
logP2.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0127 mg/mLALOGPS
logP2.59ALOGPS
logP2.92ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)10.96ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area224.45 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity203.9 m3·mol-1ChemAxon
Polarizability82.06 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as taxanes and derivatives. These are diterpenoids with a structure based either on the taxane skeleton, or a derivative thereof. In term of phytochemistry, several derivatives of the taxane skeleton exist
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassPrenol lipids
Sub ClassDiterpenoids
Direct ParentTaxanes and derivatives
Alternative Parents
Substituents
  • Taxane diterpenoid
  • Phenylpropylamine
  • Benzoate ester
  • Tricarboxylic acid or derivatives
  • Benzylether
  • Benzoic acid or derivatives
  • Benzoyl
  • Fatty acid ester
  • Fatty acyl
  • Benzenoid
  • Monosaccharide
  • Monocyclic benzene moiety
  • Acetate salt
  • Tertiary alcohol
  • Cyclic alcohol
  • Secondary alcohol
  • Polyol
  • Oxetane
  • Ketone
  • Carboxylic acid ester
  • Oxacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Structural constituent of cytoskeleton
Specific Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain (By similarity).
Gene Name:
TUBB1
Uniprot ID:
Q9H4B7
Molecular Weight:
50326.56 Da
References
  1. Gligorov J, Lotz JP: Preclinical pharmacology of the taxanes: implications of the differences. Oncologist. 2004;9 Suppl 2:3-8. [PubMed:15161985 ]
  2. Matesanz R, Barasoain I, Yang CG, Wang L, Li X, de Ines C, Coderch C, Gago F, Barbero JJ, Andreu JM, Fang WS, Diaz JF: Optimization of taxane binding to microtubules: binding affinity dissection and incremental construction of a high-affinity analog of paclitaxel. Chem Biol. 2008 Jun;15(6):573-85. doi: 10.1016/j.chembiol.2008.05.008. [PubMed:18559268 ]
  3. Snyder JP, Nettles JH, Cornett B, Downing KH, Nogales E: The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density. Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5312-6. Epub 2001 Apr 17. [PubMed:11309480 ]
  4. Belani CP, Eckardt J: Development of docetaxel in advanced non-small-cell lung cancer. Lung Cancer. 2004 Dec;46 Suppl 2:S3-11. [PubMed:15698529 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Ubiquitin protein ligase binding
Specific Function:
Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating f...
Gene Name:
BCL2
Uniprot ID:
P10415
Molecular Weight:
26265.66 Da
References
  1. Gligorov J, Lotz JP: Preclinical pharmacology of the taxanes: implications of the differences. Oncologist. 2004;9 Suppl 2:3-8. [PubMed:15161985 ]
  2. Marshall J, Chen H, Yang D, Figueira M, Bouker KB, Ling Y, Lippman M, Frankel SR, Hayes DF: A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol. 2004 Aug;15(8):1274-83. [PubMed:15277270 ]
  3. Inoue Y, Gika M, Abiko T, Oyama T, Saitoh Y, Yamazaki H, Nakamura M, Abe Y, Kawamura M, Kobayashi K: Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer. Oncol Rep. 2005 Feb;13(2):259-64. [PubMed:15643508 ]
  4. Petrylak DP: Chemotherapy for androgen-independent prostate cancer. World J Urol. 2005 Feb;23(1):10-3. Epub 2005 Feb 1. [PubMed:15685445 ]
  5. Miyoshi Y, Uemura H, Kubota Y: [Treatment of androgen-independent hormone refractory prostate cancer using docetaxel]. Nihon Rinsho. 2005 Feb;63(2):298-302. [PubMed:15714982 ]
  6. Magi-Galluzzi C, Zhou M, Reuther AM, Dreicer R, Klein EA: Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer. 2007 Sep 15;110(6):1248-54. [PubMed:17674353 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Structural molecule activity
Specific Function:
The exact function of MAP2 is unknown but MAPs may stabilize the microtubules against depolymerization. They also seem to have a stiffening effect on microtubules.
Gene Name:
MAP2
Uniprot ID:
P11137
Molecular Weight:
199524.51 Da
References
  1. McGrogan BT, Gilmartin B, Carney DN, McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008 Apr;1785(2):96-132. Epub 2007 Nov 12. [PubMed:18068131 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Structural molecule activity
Specific Function:
Non-neuronal microtubule-associated protein. Promotes microtubule assembly.
Gene Name:
MAP4
Uniprot ID:
P27816
Molecular Weight:
121003.805 Da
References
  1. McGrogan BT, Gilmartin B, Carney DN, McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008 Apr;1785(2):96-132. Epub 2007 Nov 12. [PubMed:18068131 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Structural constituent of cytoskeleton
Specific Function:
Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the ce...
Gene Name:
MAPT
Uniprot ID:
P10636
Molecular Weight:
78927.025 Da
References
  1. McGrogan BT, Gilmartin B, Carney DN, McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008 Apr;1785(2):96-132. Epub 2007 Nov 12. [PubMed:18068131 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Zinc ion binding
Specific Function:
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism and secretion of potentially harmful xenobiotics, drugs and endogenous compounds. Activated by the antibiotic rifampicin and various plant metabolites, such as hyperforin, guggulipid, colupulone, and is...
Gene Name:
NR1I2
Uniprot ID:
O75469
Molecular Weight:
49761.245 Da
References
  1. Ikezoe T, Hisatake Y, Takeuchi T, Ohtsuki Y, Yang Y, Said JW, Taguchi H, Koeffler HP: HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res. 2004 Oct 15;64(20):7426-31. [PubMed:15492266 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo IJ, Scherman D: Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol. 1994 Oct 7;48(7):1528-30. [PubMed:7945455 ]
  2. Shirakawa K, Takara K, Tanigawara Y, Aoyama N, Kasuga M, Komada F, Sakaeda T, Okumura K: Interaction of docetaxel ("Taxotere") with human P-glycoprotein. Jpn J Cancer Res. 1999 Dec;90(12):1380-6. [PubMed:10665657 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name:
ABCC10
Uniprot ID:
Q5T3U5
Molecular Weight:
161627.375 Da
References
  1. Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, Kruh GD: Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res. 2009 Jan 1;69(1):178-84. doi: 10.1158/0008-5472.CAN-08-1420. [PubMed:19118001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, Wolff AC, Carducci MA, Sparreboom A: Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther. 2009 Feb;85(2):155-63. doi: 10.1038/clpt.2008.95. Epub 2008 May 28. [PubMed:18509327 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Kobayashi Y, Ohshiro N, Sakai R, Ohbayashi M, Kohyama N, Yamamoto T: Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8. [PubMed:15901346 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G: Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest. 2002 Nov;110(9):1309-18. [PubMed:12417570 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G: Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest. 2002 Nov;110(9):1309-18. [PubMed:12417570 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G: Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest. 2002 Nov;110(9):1309-18. [PubMed:12417570 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 05, 2016 03:40